{"schema_version":"secwatch.filing_event.v1","accession":"0001740797-25-000049","form_type":"8-K","ticker":"AVAI","cik":"0001740797","company_name":"AVAI BIO, INC.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.309638+00:00","generated_at":"2026-05-17T00:39:49.040542+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Avant Technologies forms joint venture Insulinova with Austrianova for diabetes cell therapy","bullets":["AVAI and Austrianova each hold 50% of Insulinova, a JV for encapsulated insulin cell diabetes treatments.","AVAI contributes up to $1.5M in capital over 18 months for operations, plus an optional $8.5M loan for clinical testing.","Austrianova provides exclusive license to its cell encapsulation technology; Kenn Kerr CEO, Walter Günzburg Chairman.","This agreement supersedes the prior JV from Sept 19, 2025, which included Art-Islets as a party."],"urls":{"canonical":"https://secwatch.observer/filing/0001740797-25-000049","json":"https://secwatch.observer/filing/0001740797-25-000049.json","markdown":"https://secwatch.observer/filing/0001740797-25-000049.md","text":"https://secwatch.observer/filing/0001740797-25-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740797/000174079725000049/0001740797-25-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740797/000174079725000049/avai_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:39:49.040542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}